HLS Therapeutics Inc experienced a notable uptick in its stock price, reflecting investor confidence and market optimism.
In yesterday's trading session, HLS Therapeutics Inc (HLS.TO) saw its stock price rise by 5.26%, closing at CA$4.20. This positive movement comes amid strong financial performance and strategic developments that have caught investors' attention.
Investor takeaway: The recent surge in HLS Therapeutics' stock highlights the company's growth trajectory and potential for future profitability, especially with its expanding cardiovascular portfolio.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$129.93M
52W high
$5.72
52W low
$3.56
1W change
+6.33%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS · as of Oct 1, 2026
Wall Street analysts forecast HLS stock price to rise 78.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.51
+78.8% Upside
Previously C$7.48 on Sep 30, 2026
Current Price
C$4.20
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
42.5%
Annualized
90-Day Vol
33.6%
Annualized
Trend (90d)
-9.9%
Annualized drift
90d Mean
C$4.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.15 | C$3.58 – C$4.81 |
| 60 trading days | C$4.10 | C$3.33 – C$5.05 |
| 90 trading days | C$4.05 | C$3.14 – C$5.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
HLS Therapeutics has shown solid year-over-year growth in its cardiovascular portfolio, with recent financial results indicating a 25% increase in net sales. The company’s strategic initiatives, like securing reimbursements for its products, position it well for continued growth.
Bear case
Despite the positive momentum, HLS Therapeutics still has a negative profit margin of -15.24%, raising concerns about its long-term profitability and the sustainability of its growth.
Strong Financial Performance
HLS Therapeutics reported a 25% year-over-year growth in net sales from its cardiovascular portfolio in its latest financial results. This growth has boosted investor confidence and highlighted the company's ability to expand its market presence.
Advertisement
Strategic Developments
The company has successfully secured reimbursement for its product NILEMDO™ with major private payers in Canada, along with a positive recommendation for public reimbursement. These strategic moves are likely to enhance its revenue streams and solidify its market position.
Investor Sentiment
The rise in HLS Therapeutics' stock price reflects a broader positive sentiment among investors, who are increasingly optimistic about the company's growth potential and its ability to navigate the competitive landscape in the pharmaceutical industry.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
